Nuvo Research, Ranbaxy signs deal to market Oxoferin in Asian countries
PharmaBiz
The Canada-based transdermal drug development firm Nuvo Research Inc and Daiichi-Ranbaxy, the Indian subsidiary of Japanese drug major Daiichi Sankyo has entered into an exclusive license agreement for the supply and distribution of Oxoferi...
Nuvo Research announces new licensing agreement for Oxoferin
News-Medical.Net
This support is in addition to the SAB's financial support for the ongoing pre-clinical and clinical development of WF10 as a treatment for Allergic Rhinitis. In aggregate, the SAB has now committed to provide funding over a three-year peri...
Full description
Pharmalicencing
The Company’s technology concentration includes research and development on natural substances that can be used in foods, medical supplies, cosmetics and daily products.
Patient Evaluation of Retail Clinic Care
Medscape News
Common conditions that are treated include allergic reactions, upper respiratory infections, rhinitis, sinusitis, bronchitis, strep throat, otitis media, influenza, insect bites, urinary tract infections, and conjunctivitis. Patients use th...
FDA approves CSL Biotherapies' seasonal flu vaccine, Afluria for children
News-Medical-Net
CSL Biotherapies, a subsidiary of CSL Limited, one of the world’s leading manufacturers of influenza vaccine, announced that the U.S. Food and Drug Administration (FDA) has approved the company’s application for accelerated approval of its ...
Altair Therapeutics Raises $17M
socalTech.com
The firm said the funding will go to complete phase 2a trials on its lead product, which is being targeted at treating asthma, allergic rhinitis, and other inflammatory disorders.
Underlying Factors of Allergies and Asthma, Part IV
VillageSoup Belfast
... the autonomic nervous mechanism through fatigue, faulty metabolism, hypoendocrine or hyperendocrine function will result in sympathetic reactions, of which vasomotor rhinitis and ... respects, very similar to other allergic reactions.
Nuvo research provides WF10 licensing and development update
Earthtimes
This support is in addition to the SAB's financial support for the ongoing pre-clinical and clinical development of WF10 as a treatment for Allergic Rhinitis. "These agreements provide further evidence of the potential for WF10," said Henri...